论文部分内容阅读
目的观察贝那普利治疗糖尿病心肌病的临床效果。方法选取2012年9月-2014年11月医院收治的糖尿病心肌病患者120例,按照住院单双号分为观察组和对照组各60例。对照组予胰岛素、利尿剂、阿司匹林、降脂药等基础治疗;观察组在对照组基础上加用贝那普利治疗。观察、比较2组实验室指标及临床效果。结果 2组治疗后患者Hb Alc、TC、TG、hs CRP、TNF-a、LVMI均较治疗前降低,且观察组降低幅度高于对照组,差异有统计学意义(P<0.05)。观察组总有效率为93.3%明显优于对照组的68.3%,差异有统计学意义(P<0.05)。2组治疗过程中均未出现明显不良反应。结论贝那普利治疗糖尿病心肌病效果显著,并可有效改善患者预后,值得临床推广应用。
Objective To observe the clinical effect of benazepril on diabetic cardiomyopathy. Methods A total of 120 diabetic cardiomyopathy patients admitted from September 2012 to November 2014 in our hospital were selected and divided into observation group and control group according to hospitalized single and double numbers respectively. The control group was given insulin, diuretic, aspirin, lipid-lowering drugs and other basic treatment; observation group on the basis of the control group plus benazepril treatment. Observe, compare two groups of laboratory indicators and clinical effects. Results The Hb Alc, TC, TG, hs CRP, TNF-a and LVMI of the two groups after treatment were lower than those before treatment, and the reduction rate of the observation group was higher than that of the control group. The difference was statistically significant (P <0.05). The total effective rate in the observation group was 93.3%, which was significantly better than that in the control group (68.3%) (P <0.05). No significant adverse reactions occurred in the two groups during the course of treatment. Conclusion The effect of benazepril in treatment of diabetic cardiomyopathy is significant and can effectively improve the prognosis of patients. It is worthy of clinical application.